Summit’s disappointing survival readout raises stakes for full data
Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: How mature, exactly, were the data? The biotech on Friday shared new Phase 3 data for ivonescimab, its PD ...
Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: How mature, exactly, were the data?
The biotech on Friday shared new Phase 3 data for ivonescimab, its PD ...
